L-2-(N-Pteroyl)amino-3-(N-phosphonoacetyl)aminopropanoic acid was synthesized as an analogue of the putative y-phosphorylated intermediate in the enzyme-catalyzed y-glutamation of folic acid by folylpolyglutamate synthetase (FPGS) . N-(Benzyloxycarbonyl)-L-aspartic acid was converted in four steps to methyl L-2-(N-benzyloxycarbonyl)amino-3-aminopropanoate, and the latter was allowed to react with p-nitrophenyl dimethoxyphosphonoacetate to obtain methyl L-2-(N-benzyloxycarbonylamino)-3-(N-dimethoxyphosphonoacetyl)aminopropanoate. After catalytic hydrogenation, the resulting amine was coupled to N10-formylpteroic acid via the mixed carboxylic-carbonic anhydride method, and the three ester groups were removed by sequential treatment with Me 3 SiBr in DMF and NaOH in DMSO. When the last step was performed only with NaOH/DMSO, one of the phosphonate esters remained intact, giving L-2-(N -pteroyl )amino-3 -(N -monOInethoxyphosphonoacetyl )aminopropanoic acid. Also synthesized as a potential FPGS inhibitor was N a-(4-amino-4-deoxy-N1o-methylpteroyl)-NE-phosphonoacetyl-L-Iysine. The ability of these phosphonoacetyl derivatives to inhibit catalytic addition of L-glutamic acid to folic acid proved to be very low, suggesting that replacement of the CH 2 C(=O)OP(=O)(OHh moiety by NHC(=O)CH 2 P(=O)(OH)2 may place the terminal phosphonyl group in an unfavorable spatial orientation for binding to the enzyme.
Introduction
Consecutive addition of one or more L-glutamyl moieties to the y-carboxyl group in natural folates and glutamate-containing antifolates plays a critical role in the cellular pharmacology of these physiologically important molecules § Author to whom correspondence should be addressed.
(reviewed III refs. 1 and 2). The reaction is catalyzed by the enzyme folylpolyglutamate synthetase (FPGS), whose requirement for normal cell growth was originally inferred from the observation that FPGS-deficient cells are auxothrophic for thymidine and a purine (3, 4) . More recently a required role for FPGS in normal cell growth was demonstrated by Priest and coworkers (5), using an antisense expression system to Ronald Forsch et af. : Folic acid y-glutamation by fc>lylpolyglutamate synthetase down-regulate FPGS aCtiVIty in CCRF-CEM human leukemic cells. Commensurate decreases in total reduced folate pools, thymidylate synthesis, and growth rate were observed (5) . The multiple negative charges in the side chain of folyl y-polyglutamates retard the efflux of these molecules from cells, and also makes them better substrates than the parent monoglutamate for various folate-metabolizing enzymes, such as thymidylate synthase . Thus, y-polyglutamation of natural folates serves a dual purpose, in helping to maintain adequate cofactor pools while ensuring that reduced folate cofactors are utilized with maximum catalytic efficiency. In dle cellular pharmacology of a number of important antifOlates, y-polyglutamation serves a similar dual purpose except that tighter enzyme binding enhances inhibitor activity rather than substrate activity. The use of FPGS inhibitors as drugs was proposed more than 15 years ago (6) . Since then, a number of potent substrate analogues have been tested, including for example compounds with a homocysteic acid (7a-c), 2-amino-4-phosphonobutanoic acid (7b, 7c, 8), ornithine (7c,9a-f), or 2-amino-4-( IH -tetrazol-1-yl)butanoic acid (10) side chain. Other analogues with y-substitution on the glutamate moiety ( lla-c) or with fluorine substitution on the ornithine moiety (12) have also been studied. However none of the substrate analogues studied to date have shown enough preclinical activity to warrant clinical triaL An elegant isotopic study (13) utilizing folic acid (1 ) as the substrate suggested that the first step along the FPGS reaction coordinate is the transient formation of the acyl phosphate intermediate 2 (Fig. 1 ). This is followed by rapid phosphate displacement by the incoming glutamate moiety to give folyl-y-L-glutamate (3). Further rounds of phosphate transfer trom A TP and phosphate displacement by L-glutamate generates oligomers of different chain-length depending on the kinetics of each successive elongation step.
On the basis of this mechanism, a reasonable approach to the development of potent inhibitors of the FPGS reaction might be to design stable analogues of the acylphosphate intermediate 2. A preliminary step in this direction was taken by us some years ago with the observation that the N-(phosphonoacetyl)-L-lysine analogue 4 (Scheme 1) could retard the y-glutamation of folic acid by murine FPGS (6) . However two structural features of this molecule were llr1desirable in terms of inhibitor design. In the first place, as a 2,4- diamino derivative, 4 would almost certainly be a potent inhibitor of dihydrofolate reductase (DHFR), so that any effect on cell growth would not be unequivocally attributable to FPGS inhibition alone. Secondly, the side chain in 4 was longer by two atoms dlan that of the putative acylphosphate intermediate 2, an arrangement that we suspected would be less than optimal for binding to the enzyme active site. In the present paper we present details of our original synthesis of 4, and also report the synthesis of L-2-(N-pteroyl)amino-3 -(Nphosphonoacetyl)aminopropanoic acid (5 ) (Scheme 2). The latter is viewed as a closer analogue of 2, in that (a) the heterocyclic moiety is a 2-amino-4-hydroxypteridine rather than a 2,4-diaminopteridine, and (b) the side chain is of the same length as that of 2. Indeed, the only difference between 1 and 2 is that the CH 2 P( =0)0 moiety in the side chain is replaced by NHP( =0 )CH 2 •
Chemistry
As indicated in Scheme 1, the synthesis of 4 was accomplished in a single step, albeit in modest yield, from phosphonoacetyl chloride and the previously described compound 4-amino-4-deoxy-N)O-methylpteroyl-L-lysine (6) (l4a, b) . The reaction was carried out under SchottenBaumann conditions, with the amine being added slowly to a solution of the acid chloride in aqueous dioxane containing excess NaOH. The product was partially desalted b y passing it through a Sephadex G 1 0 size-exclusion column with water as the eluent, and was further purified b y chromatography on a DEAE-cellulose column which was eluted successively with deionized water and 3% ammonium bicarbonate. The ammonium bicarbonate eluent was monitored by TLC, and fractions containing a single spot were combined and freeze-dried. Microchemical analysis showed 4 to be a partial ammonium salt, and because the final test sample was dried only by lyophilization (no heat ) it also contained 4.5 molecules o f water.
As outlined in Scheme 2, the synthesis of 5 began with N-(benzyloxycarbonyl)-L-aspartic acid (7) . The procedure of Scholtz and Bartlett (15) , with minor modifications, was used to convert 7 to the oxazolidinone 8 b y reaction with p araformaldehyde and p-T sOH, and thence to the protected L-2,3-diaminopropanoic acid derivative 9 via Curti us rearrangement. Treatment of 9 with NaOMe gave the ester 10, which on acidolysis with p-TsOH was converted to the tosylate salt 
Scheme 2. proton as a singlet at cS 8.62, the phenyl protons as a pair of doublets at cS 6.53 ( 3 ' ,5 '-H) and 7.55 (2',6 ' -H) respectively, and the CH 2 group next to P as a doublet at 8 3 .52, partially overlapping the I3-CHz group . No signals attributable to OMe groups or the N 'O -formyl group were detected, showing that de protection was complete. fu in the case of 4, the microanalytical data were consistent with a hydrated monoammonium salt.
The major product of the reaction of 16 with one equivalent of NaOH was the monomethoxyphosphinyl derivative 17. As with 5, purification of 17 was achieved by C' 8 silica gel preparative HPLC, but with 5% rather 4% MeCN as the organic phase. The structural identity of 17 was established from its 'H NMR spectrum, which showed a P-OMe doublet overlapping the I3-CHz doublet, but was otherwise very similar to Pteridines/ Vol. 10/ No. 1 that of 5 after allowing for solvent differences (D 2 0 versus DMSO-d 6 ) . Microchemical analysis again showed 17 to be a hydrated ammonium salt. It may be noted that a minor HPLC peak which eluted more slowly than 17 was observed during its purification, which might have been 18. However because we were concerned that it would have very poor aqueous solubility, this slower-moving product was not collected and further efforts to isolate and characterize 18 were not deemed worthwhile.
Interaction with FPGS
Experiments were performed to determine whether 4, 5 and 17 inhibit FPGS-catalyzed addition of L -glutamic acid to folic acid under the assay conditions reported previously ( 19) . The ability of these compounds to block the polyglutarnation reaction was found to be very poor, with only slight inhibition being observed at 100 It is of interest to note that an alternative approach to the development of mechanism-based inhibitors of FPGS was recently described by Tsukamoto and coworkers (22) in the form of compound 26, which can be viewed as a bisubstrate analogue combining 1 and L-glutamate into a single molecule . Interestingly, 26 may be also viewed an analogue of 2 itself (i.e., a product analogue). The 1<; of 26 as an inhibitor of the catalytic addition of L-glutamate to MTX in the presence of human FPGS was found to be 0.12 /lM, whereas the corresponding ornithine analogue had a 1<; of 3.2 /lM (22) . While 26 is not more potent than some of the other ornithine analogues discussed abo\"C, preyious structureactivity correlation studies (9.1 -c ) suggest that the potency of 26 against FPGS \yould probabh' be enhanced by replacing the ~I "-methd by hydrogen and by replacing ~; and X ' by carbon . On the other hand a disadvantage of 26 as an FPGS-targeted drug is that its affinity for DHFR is three orders of magnitude higher than its affinity for FPGS (22) . As a result, any cell growth inhibition observed with this compound is most likely due to DHFR rather than FPGS inhibition. Nevertheless, the fact that 26 binds better than 5 to FPGS is of interest, in that it suggests that structures that resemble later intermediate species along the FPGS reaction coordinate may represent a more promising approach to the design of effective mechanism-based inhibitors than structures based on the putative early intermediate 2 .
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Experimental Section
General IR spectra were obtained on a Perkin-Elmer Model 781 double-beam recording spectrophotometer. Shoulders and very weak peaks are omitted . IH ~1\1R spectra at 60 MHz were recorded on a Varian Model EM360L instrument, using l'vle 4 Si as the internal reference for spectra in CDCI, and DMSO-d 6 and Me 3 SiCD 2 CD 2 COONa as the internal reference for spectra in D 2 0. IH NMR spectra at 500 MHz were determined on a Varian VXR500 instrument. TLC analyses were on Whatman MK6F silica gel plates, with spots visualized under a 254-nm UV light. Products for elemental analyses were dried in vacuo at 70 n C over PzO". Melting points were determined in Pyrex capillary tubes in a Mel-Temp apparatus ( Laboratory De,'ices, Inc., Cambridge, MA). 4-Amino-4-deoxy-N 10 -methylpteroyl-L-lysine (6) ( 14a,b) and XI O -tormylpteroic acid (15) ( 18) were prepared as described earlier. N-Benzyloxycarbonyl-L-aspartic acid was purchased from Bachem, Torrance, CA, and other chemicals from Aldrich, 1\1ilwaukee, WI. Microanalyses were carried out b\' Quantitati\"C Technologies, Inc., Whitehouse, ~J. and "'ere ,,·ithin 0.4% of theoretical values. (4) A suspension of phosphonoacetic acid (2.0 g, 0.014 mol) in freshly distilled SOCl 2 (65 ml) was stirred at 50"C (oil bath) for 3 h, then at 63°C for 4 h . Excess SOCl z was removed by rotary evaporation, and the last traces were co-distilled azeotropically with toluene to afford an oil, which was taken up in dioxane ( 28 ml), glVlllg a solution assumed to contain 0.5 mmol/m!. This stock solution was used directly in the next step .
.\ ""' " -( -I-A III illo--I-deoxy-N 11 , -methylpteroyl)-~ -(phospholloacer.-!)-L-lnille
A suspension of 6 (50.7 mg, 0.1 mmol) in H 2 0
Ronald rorsch et at.: Folic acid y-glutamation by folylpolyglutamate synthetase (IS ml) was adjusted to pH 11.2 by dropwisc addition of I N NaOH . When all the solid dissolved, the solution was cooled to 5°C and stirred with simultaneous dropwise addition of I N NaOH (3.75 ml) and a portion of the stock solution of phosphonoacetyl chloride in dioxane prepared above (2 ml, assumed to contain 1.0 mmol). Addition was performed in such a manner as to keep the pH between 7.0 and 9.5. The progress of the reaction was monitored by TLC (silica gel, 3:2:1 n-BuOH-H 2 0-AcOH), which showed spots with~· 0.15 (4),0.30 (6), and 0.36. When reaction appeared to be complete, the solution was diluted to 10 ml and passed through a column of Sephadex G-I0 (54 x 1.3 cm, swollen in H 2 0 from 24 g of dry powder) with H 2 0 as the eluent. Fractions were monitored by TLC (silica gel, 6:4:3 n-BuOH-H 2 0-AcOH), and tubes showing a spot with ~. 0.25 were combined and freeze-dried to a yellow powder (235 mg) which was not fully desalted. The powder was suspended in H 2 0 (10 ml) at pH 6.5, a small amount of insoluble material was removed by filtration, and the filtrate was adjusted to pH 2.0 and filtered again. The filtrate was freezedried, and the residue was triturated successively with cold Me2CO and MeOH to obtain a yellow powder (103 mg). This solid was dissolved in 3% NH 4 HC0 3 (1.5 ml), the pH was adjusted to 11.0 with 28% NH 4 0H, and the solution was applied onto a column of DEAE-cellulose (DE-52, HCO~ form, 1.3 x 17 cm) which was eluted successively with distilled H 2 0 (160 ml) and 3% 
4-Nitrophenyl Dimethoxyphosphonoacetate (12)
Trimethyl phosphonoacetate (9.10 g, 0.05 mol) was stirred and treated dropwise over 3 min with 1 N NaOH (50 ml, 0.05 mol). The solution was left at room temperature for 18 h and passed through a column of Dowex 50W-X2 (H+ form, 2 X 25 cm). The acidic fractions were combined and evaporated under reduced pressure. After several cycles of azeotropic distillation with toluene, dimethoxyphosphonoacetic acid was obtained as an oil (9.79 g); lH NMR (CDCI3) 8 3 0) . A solution of the crude acid in EtOAc (l00 ml) was treated directly with p-nitrophenol (6.95 g, 0.05 mol) followed by DCC (10.3 g, 0.05 mol) . The reaction mixture became warm, and TLC (silica gel, 1:1 acetoneether) showed the formation of a new spot at ~. 0.5, along with unreacted p-nitrophenol (Rr 0 .8).
A second portion of DCC (5.15 g, 0.025 mol) was added, and when TLC showed that all the pnitrophenol was consumed, the reaction was quenched by dropwise addition of 98% formic acid (1 ml). The solid was filtered and the filtrate was evaporated to obtain 12 as an oil which was used directly in the formation of 13 trom 11 as described in the next step.
Methyl L-2-(N-Benzyloxycarbonylamino)-3-N-(dimethoxyphosphonoacetyl)aminopropanoate (J 3)
A mixture of NU-(benzyloxycarbonyl)-L-aspartic acid (7) (13.4 g, 0.05 mol), paraformaldehyde (2.5 g, 0.083 mol), and p-TsOH' H 2 0 (0.5 g) in toluene (100 ml) was heated to reflux in a DeanStark apparatus for 30 min and allowed to cool to room temperature. EtOAc was added to the twophase mixture until it became homogeneous, and the solution was washed to neutrality with H 2 0. The product was then extracted into 5% NaHC0 3 , and the aqueous layer was acidified with HCI and extracted with EtOAc. The EtOAc layer was washed with H 2 0 and evaporated under reduced pressure to afford 8 as a thick oil from which the last traces of solvent were removed by heating in vacuo at 60°C; yield 13.6 g (98%). A dried sample of 8 (12.2 g, 0.044 mol) and DPPA (12.1 g, 0 .044 mol) in t-BuOH (70 ml) containing Et3N (6.12 ml, 4.44 g, 0 .044 mol) was heated under reflux for 18 h. The solvent was evaporated under reduced pressure, the residue was partitioned between CHCI 3 and 5% NaHC0 3 , and the CHCl 3 layer was washed with 1 N HCI and evaporated. The resulting crude 9 was taken up directly in MeOH (100 ml), and the solution was cooled to O°C and stirred while adding NaOMe (2.7 g) in small portions over 5 min. After 15 min the reaction mixture was quenched with glacial AcOH (4 ml) and evaporated to dryness to obtain impure 10 (14.7 g) as an oil. A portion of this material ( 11.1 g) was purified by flash chromatography on silica gel (4 X 9 cm) with CHCl 3 as the eluent. Fractions containing a single TLC spot with Rr 0.6 (silica gel, CHCI 3 ) were pooled and evaporated to obtain pure 10 (6.64 g, 57%). Although others have reported this compound to melt at 88-90 n C (2 3 ), we were un able to obtain it in a crystalline state. A solution of 10 ( 5.85 g, 0.0167 mol) in toluene (80 ml ) containing p-TsOH ·H 2 0 ( 3.04 g, 0 .016 mol ) was boiled in an open flask for 15 min to allow H 2 0 to escape, and the cooled reaction mixture was concentrated to dryness b y rotary evaporation. The residue, consisting of the crude tosylate salt 11 , was dissolved directly in CH 2 Cl 2 (40 ml) and to this solution was added a solution of 12 (4 .91 g, 0 .017 mol ) in C H 2 C I 2 (40 ml) followed b y Et~N (7. 
3-(N-Phosphonoacetyl)amino-2-L-(N-pteroy lamino) propanoic Acid (5)
A solution of 13 (804 mg, 2.0 mmol) in MeOH (25 ml) containing MC,SiCI ( 381 Ill , 326 mg, 3.0 mmol), used as a com'enient source of anhydrous HCl, was shaken with 5% Pd-C ,60 m g) under 3 atm , of H z for 18 h . The catah'st was removed by filtratio n , and the solvent was evaporated to obtain crude 14· HCl (610 mg, 100%) as a foam w hich was used directly in the A suspension of NIO-fonnylpteroic acid (15) (340 mg, 1.0 mmol ) in dry DMF (10 ml ) was treated with Et3N (167 Ill, 121 mg, 1.2 mmol ) and i-BuOCO C l ( 156 Ill, 164 mg, 1.2 mmo l) and placcd in an ultrasonicarion bath tor 10 min until most of the solid dissolved . To the solutio n was then added a solution of 14 ' HCI (3 05 mg, 1.0 mmol ) in dry DMf (4 ml ) followed by Et3N ( 139 Ill, 101 mg, 1.0 mmol ). After two additional cycles of additio n of i-BuOCOCI (65 /--ll, 68 m g, 0.5 mmol ) followed by Et3N (69 /--ll , 50 mg, 0 .5 mmol ) and 14 · HCl ( 151 mg, 0 ,5 mmol ) followed by Et3N (69 /--ll, 50 mg, 0 .5 mmol ), the solution was added dropwise with stirring into H zO (200 ml ), The pH was adjusted to slightly below 7.0 with glacial AcOH, and the fine precipitate which formed was collected on a g lass tiber filter. The solid was ground up, suspended in 2:1 CHCI 3 -MeOH, and sonicated at 50 n C until no more of it dissolve d. After filtration to remove the insoluble mate rial , the filtrate was diluted w ith Et 2 0, and the precipitate was collected t o obtain 16 as a light-yellow powder ( 11 7 m g); mp> 200"C dec; ~-0. Compound 16 (56 mg, 0 .095 mol ) was suspended directly in dry DMF (2.5 ml ) and kept at 50"C until all the solid dissolved. The solution was then cooled to room temperature , treated with Me 3 SiBr ( 396 /--ll, 459 mg, 0.03 mmo l), and left to stand tor 3 days. The excess Me.,SiBr was removed b y rotary evaporation, the remaining DMF solution was treated w ith 1 N NaO H ( 10 ml ), and after 15 min at room temperature the reaction was termin at ed bv bringing the pH to 7.0 with HC!. Preparative HPLC batch purification on C" silica gel ,,'as performed with 4 % MeCN in () . ()~ .\[ );H 4 0Ac, pH 6.9 as the eluent at a flow r.:ite 10 m l/ min. T \\ 0 peaks were observed, with .l pe.lk height rati o of ca . 3 :2 and elution tim es of 1:; and 21 min , re spec ti\-ely. The s]o,,'er peak was a minor but inten sely LTV-absorbing impurity, and \\-as d isca rd ed. Pooled eluents containing the taster-mO\-ing peak \\-ere concentrated to dryness by rotary c\'aporation and two cycles of lyophilization to obtain 5 as a pale greenishyellow solid (23 m g) 
-N -( M ethoxyphosphono )acetylamino-2 -L -( Npteroylamino)propanoic Acid (17)
A solution of crude 16 (113 mg, 0.192 mmol) in DMSO (2 ml) was stirred and treated dropwise over 3 min with 1 N NaOH (2 ml, 2 mmol). The clear solution was kept at 60°C in a water bath for 5 min, then cooled, diluted with H 2 0 (15 ml), and adjusted to pH 7 with 10% AcOH. Preparative HPLC (C 18 silica gel, 5% MeCN in 0 .05 M NH 4 0Ac, pH 6.9, 10 ml/min) showed two peaks (5: 1 ratio) with elution times of 7 min and 9 min, respect-ively. Pooled fractions containing only the larger, faster-moving peak were collected, concentrated by rotary evaporation, and freeze-dried. The residue was taken up in H 2 0 with addition of a few drops of 28% NH 4 
